Description

27,69,000 equity shares of Venmax Drugs And Pharmaceuticals Ltd listed on BSE with effect from December 30, 2025, issued on preferential basis pursuant to conversion of warrants.

Summary

BSE has approved the listing of 27,69,000 equity shares of Venmax Drugs And Pharmaceuticals Ltd (Scrip Code: 531015) with effect from December 30, 2025. These shares were issued at Rs. 20/- per share (face value Rs. 10/- plus premium of Rs. 10/-) to non-promoters on a preferential basis pursuant to conversion of warrants. The shares rank pari-passu with existing equity shares and are subject to lock-in until July 13, 2026.

Key Points

  • 27,69,000 new equity shares listed and permitted to trade from December 30, 2025
  • Scrip Code: 531015
  • Face value: Rs. 10/- per share
  • Issue price: Rs. 20/- per share (including premium of Rs. 10/-)
  • Issued to non-promoters on preferential basis pursuant to warrant conversion
  • ISIN: INE154G01022
  • Shares rank pari-passu with existing equity shares
  • All new shares subject to lock-in period

Regulatory Changes

No regulatory changes. This is a routine listing notification following preferential allotment procedures.

Compliance Requirements

  • Trading members are informed of the new securities available for trading
  • Lock-in restrictions must be observed for all 27,69,000 shares until July 13, 2026
  • Shares issued in three tranches with distinct distribution numbers for tracking

Important Dates

  • August 16, 2025: First allotment of 20,55,000 shares (Dist. Nos. 5238931-7293930)
  • August 30, 2025: Second allotment of 3,60,667 shares (Dist. Nos. 7293931-7654597)
  • September 16, 2025: Third allotment of 3,53,333 shares (Dist. Nos. 7654598-8007930)
  • December 30, 2025: Effective date for trading of listed securities
  • July 13, 2026: Lock-in period expires for all 27,69,000 shares

Impact Assessment

Market Impact: Low. This is a company-specific listing event involving preferential allotment to non-promoters through warrant conversion. The total number of shares (27.69 lakhs) represents additional equity capital for Venmax Drugs And Pharmaceuticals Ltd.

Operational Impact: Minimal. Trading members can trade these securities from December 30, 2025, subject to lock-in restrictions until July 13, 2026. The staggered allotment across three dates in August-September 2025 suggests phased warrant conversion.

Shareholder Impact: Moderate dilution for existing shareholders. The preferential allotment to non-promoters increases the public shareholding of the company.

Impact Justification

Routine listing notification for preferential allotment to non-promoters; limited market-wide impact, affects only specific company shareholders